Investment Thesis:
Pluristem (PSTI) is among the cell therapy companies which are racing to completion of a Phase III trial and initiation of two others in the coming months which look to address unmet needs in the medical community. Pluristem primarily utilizes two different placenta-derived cell products, (PDX-PAD and PLX-R18) which look to address a wide collection of therapeutic needs. Their lead product indications are Critical Limb Ischemia [CLI], Hip Fracture recovery and Acute Radiation Syndrome [ARS] (all Phase III) in addition to a Phase II trial in Intermittent Claudication [IC]. Given their